´ëÇÑ´ç´¢º´ÇÐȸ 2023 International Congress of Diabetes and Metabolism(3ÀÏÂ÷) : 2023-10-21
±³À°ÀÏÀÚ : 2023-10-21
±³À°Àå¼Ò : °æÁÖ È¹éÄÁº¥¼Ç¼¾ÅÍ
±³À°ÁÖÁ¦ : 2023 International Congress of Diabetes and Metabolism(3ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ
´ã´çÀÚ : ÀÌ¿¬ÁÖ
¿¬¶ôó : 02-714-9071
À̸ÞÀÏ : diabetes@kams.or.kr
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 1200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 6 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 450,000¿ø
ºñ°í "»çÀüµî·Ï
Àü¹®ÀÇ: ȸ¿ø 28¸¸¿ø / ºñȸ¿ø 35¸¸¿ø
Àü°øÀÇ ¹× ºñÀÇ»ç: ȸ¿ø 18¸¸¿ø / ºñȸ¿ø 23¸¸¿ø
ÇöÀåµî·Ï
Àü¹®ÀÇ: ȸ¿ø 37¸¸¿ø / ºñȸ¿ø 45¸¸¿ø
Àü°øÀÇ ¹× ºñÀÇ»ç: ȸ¿ø 25¸¸¿ø / ºñȸ¿ø 27¸¸¿ø"
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10¿ù 21ÀÏ Room 1 (3F, HICO) 08:00~09:00 What should we consider when choosing DPP-4 Inhibitors for elderly patients? Á¤Ã¢Èñ(¿ï»êÀÇ´ë ³»°ú)
±³À°½Ã°£ 10¿ù 21ÀÏ Room 3 (3F, HICO) 09:00~09:25 Monogenic diabetes Toni Pollin(University of Maryland USA)
±³À°½Ã°£ 10¿ù 21ÀÏ Room 3 (3F, HICO) 09:25~09:50 Immune checkpoint inhibitor induced diabetes Yu Mi Kang(Harvard University USA)
±³À°½Ã°£ 10¿ù 21ÀÏ Room 3 (3F, HICO) 09:50~10:15 Characteristics and clinical course of diabetes of the exocrine pancreas ÇѽÂÁø(¾ÆÁÖÀÇ´ë ³»°ú)
±³À°½Ã°£ 10¿ù 21ÀÏ Room 3 (3F, HICO) 10:15~10:40 Post-transplantation diabetes, current status and new treatment ¾çö¿ì(°¡Å縯ÀÇ´ë ½ÅÀå³»°ú)
±³À°½Ã°£ 10¿ù 21ÀÏ Room 1+2+3 (3F, HICO) 11:00~11:40 Endotypes of type 2 diabetes in East Asians ¹Ú°æ¼ö(¼¿ïÀÇ´ë ³»°ú)
±³À°½Ã°£ 10¿ù 21ÀÏ Room 1 (3F, HICO) 12:00~13:00 Optimal combination use of SGLT2i and DPP-4i À̽Âȯ(°¡Å縯ÀÇ´ë ³»°ú)
±³À°½Ã°£ 10¿ù 21ÀÏ Room 3 (3F, HICO) 13:00~13:25 Overview of residual risks after adapting current prevention modalities Frederik Persson(Steno Diabetes Center Copenhagen Denmark)
±³À°½Ã°£ 10¿ù 21ÀÏ Room 3 (3F, HICO) 13:25~13:50 The present and future of the management of type 2 heart failure ±è°æÈñ(ÀÎõ¼¼Á¾º´¿ø ½ÉÀå³»°ú)
±³À°½Ã°£ 10¿ù 21ÀÏ Room 3 (3F, HICO) 13:50~14:15 What to do next to prevent diabetic retinopathy? ±èÀ±Àü(¿ï»êÀÇ´ë ¾È°ú)
±³À°½Ã°£ 10¿ù 21ÀÏ Room 3 (3F, HICO) 14:15~14:40 Paradigm shift in clinical treatment for diabetic kidney disease ±è¹Ì°æ(°è¸íÀÇ´ë ³»°ú)